MEGAN DAVIS: Open Payments
NPI 1255623609 · FAYETTEVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,580 in 19 payments from 9 companies in 2025. Trend: 2023 $236 · 2024 $367 · 2025 $8,580
Travel & lodging: $8,287Food & beverage: $293
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 10 | $8,451 |
| Novartis Pharmaceuticals Corporation | 2 | $27 |
| JAZZ PHARMACEUTICALS INC. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| ABBVIE INC. | 1 | $14 |
| AstraZeneca Pharmaceuticals LP | 1 | $13 |
| Exelixis Inc. | 1 | $13 |
| PharmaEssentia USA Corporation | 1 | $13 |
Products named: ENHERTU, ZEPZELCA, FRUZAQLA, ELAHERE, Fabhalta, CABOMETYX, BESREMI, SCEMBLIX.
Industry payments across AR — which companies pay providers there.
